Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daclatasvir + asunaprevir + beclabuvir
- Development stage
- Phase 3
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Daclatasvir + asunaprevir + beclabuvir** is an oral fixed-dose combination of three small-molecule direct-acting antivirals developed by Bristol Myers Squibb for chronic hepatitis C virus infection. Daclatasvir inhibits the HCV NS5A replication complex, asunaprevir inhibits the HCV NS3/4A serine protease, and beclabuvir is a nonnucleoside inhibitor of the HCV NS5B RNA-dependent RNA polymerase. The combination was marketed in Japan as **Ximency** for improvement of viremia in patients with genotype 1 chronic hepatitis C or compensated cirrhosis, administered as two tablets twice daily after meals for 12 weeks.
- Brand names
- Ximency
- Other names
- 3DAA regimendaclatasvir + asunaprevir + BMS-791325daclatasvir/asunaprevir/beclabuvirDCV 3DAA regimenDCV3DAA regimenDCV-3DAA regimenDCV-TRIODCV/ASV/BMS-791325
02
Targets
NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on daclatasvir + asunaprevir + beclabuvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daclatasvir + asunaprevir + beclabuvir.